PepGen Inc. (PEPG)
NASDAQ (NGS) NASDAQ (NGS) Primary 
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PepGen (PEPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data Transcript
PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data Transcript
PepGen, Inc. (NASDAQ:PEPG) Receives Consensus Recommendation of “Moderate Buy” from Analysts
PepGen, Inc. (NASDAQ: PEPG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price objective
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44%
The mean of analysts' price targets for PepGen (PEPG) points to a 75.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PepGen: DMD Discontinued, Ways To Go With DM1
PepGen Inc. (PEPG) has seen its DM1 trials advance to phase 2 with a great reaction from markets. PEPG discontinued its DMD trials, which explains some of the reduced R&D expenses in the last 3 months and also some of the stock's declines earlier in the year. With only $45 million in net cash and marketable securities and maybe towards $1 billion in future R&D costs, potential equity raises with reflexivity risk are a consideration.
PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls
On Tuesday, PepGen Inc. PEPG announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the company can review results from the 10 mg/kg cohort.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy
PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
